Team of experts mentored by Nobel Laureate
BOARD OF DIRECTORS
Stuart E. Siegel, M.D., Chairman
Janusz Maria Sowadski, Ph.D., Founder, CSO
Eric Ladizinsky, Co-Founder, Member
David M. Doyle, Co-Founder, Sec / Tres., CEO
SCIENTIFIC ADVISORY BOARD
FOUNDER/CHIEF SCIENCE OFFICER
Janusz Maria Sowadski, Ph.D., is a scientist and entrepreneur who discovered the first crystal structures of key oncogenic signaling molecule-phosphatases and kinases. He is an author of over sixty articles (cited 7294 times ) and nine patents and patent applications. His numerous crystallographic and modeling discoveries in the field of protein kinases have opened the market for personalized targeted oncology treatments. Most notably, in 1991, he discovered the first three-dimensional structure of protein kinase (PKA), which led to the development of Gleevec®, the world’s first orally-administered targeted oncology drug. Janusz M. Sowadski is the recipient of US Supercomputing Award (Wherle Award).
CHAIRMAN OF THE BOARD
Stuart E. Siegel, M.D., was a Professor of Pediatrics and Medicine at the Keck School of Medicine of USC as well as the Director of the Center for Global Health at Children’s Hospital Los Angeles (CHLA). He is also the Founding Director of the Children’s Center for Cancer and Blood Diseases and the Center for International Health at CHLA,and the first holder of the Stuart E. Siegel, M.D. Endowed Chair in Pediatric Oncology at Keck School of Medicine of USC. He led one of the largest academic Pediatric Hematology-Oncology programs in the nation and among many innovative accomplishments, developed the first comprehensive program for the psychosocial aspects of pediatric cancer.
CHAIR/IP ATTORNEY, DLA PIPER
Dr. Lisa Haile concentrates on patent protection. Dr. Haile has special technical experience in molecular biology, immunology, cell biology, regenerative medicine including ESCs, iPSCs, pSCs, diagnostics, therapeutics, theranostics, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Haile is a member of DLA Piper’s Executive Committee.
Thomas M. Wheeler,M.D., serves as the W. L. Moody, Jr., Professor and is the former Chair of the Department of Pathology & Immunology at BCM. He serves as a member of the Editorial Advisory Board at Medscape, LLC., and is editor in chief of Medscape Reference, Pathology. He also serves on the Medical Advisory Boards of Insightec, Nucleai, and Biofluidica. Dr. Wheeler is board certified in anatomic pathology, clinical pathology, and cytopathology and has served 38 years in academia, with special focus on clinicopathologic correlations in prostate cancer.
Eric Ladizinsky is Co-Founder/Chief Scientist at D Wave Sytems Inc. He is a senior scientific management executive with a strong background in physics, engineering, materials, manufacturing and team building. Mr. Ladizinsky leads D-Wave’s technical effort to develop the superconducting integrated circuit fabrication process and is often called upon to evangelize on all aspects of quantum computing. At Northrop Grumman Space Technology (formerly TRW, Inc.), he ran a multi-million dollar DARPA program in Quantum Computing using superconducting integrated circuit technology. Mr. Ladizinsky has a BSc. Physics and Mathematics degree from the University of California, Los Angeles and is an Adjunct Professor of Physics at Loyola Marymount University.
ADVISOR - Cell Assays
Andrzej Ptasznik, M,D, Ph.D., Fox Chase Cancer Center, Philadelphia: His academic career was market by several discoveries, including the new signaling mechanism and paradigm for the process of Ras activation by a number of G protein-coupled receptor systems, signaling cross talk between the BCR-ABL oncoprotein and chemokine signaling in leukemia, the first use of siRNA to validate therapeutic targets in primary leukemia cells, identification of Lyn as the important target for treating patients with drug resistant hematologic malignancies. Prior employment: he completed his postdoctoral fellowship at Scripps Research Institute, La Jolla, California and served on the faculty at University of Pennsylvania, Philadelphia and Cedars-Sinai Medical Center, Los Angeles.
Tony Hunter,Ph.D., made the seminal discovery, more than three decades ago, that the addition and subtraction of phosphate molecules to proteins on tyrosine, one of the 20 amino acids, allows cells to control when key proteins are on standby and when they are active. In cancers, he went on to show that growth was switched into an always-on mode by the malfunctions of these phosphates. Since then, his lab has led the field in understanding how chemical additions to proteins control the cell cycle and growth. Hunter uses cutting edge molecular, genetic and cell biology techniques to probe how these programs interact with each other.
Robert K. Suto, Ph.D., President, XTAL As a biochemist with a thorough knowledge of structure-guided drug discovery, Dr. Suto has now been involved, through XTAL, in the discovery and development projects of over sixty companies. During post-doctoral studies with Professor Karolin Luger at Colorado State University, he conducted X-ray crystallography studies of nucleosome core particles containing histone variants and DNA binding polyamide ligands. Dr. Suto is currently serving as a co-chair of MassBio’s Drug Discovery Working Group. The mission is to provide a forum for drug discovery and early development executives, managers and researches to exchange ideas, information and resources in order to expedite the discovery and validation of new targets and drugs.
Walter (Wally) Gilbert,Ph.D., is a renowned scientist who was awarded the 1980 Nobel Prize in Chemistry for his discovery of a method for rapid DNA sequencing. His forty year academic career at Harvard University was marked by many discoveries, including messenger RNA, genetic repressors, DNA sequencing, and the first expression of insulin in bacteria. Dr. Gilbert is the Carl M. Loeb University Professor Emeritus at Harvard University. He is currently a managing director at BioVentures Investors, a venture capital fund in Wellesley, MA. In 1978 Dr. Gilbert co-founded Biogen, the world’s oldest independent biotechnology company. As CEO, Dr. Gilbert oversaw Biogen’s Initial Public Offering in 1983.
Davide Moiani, Ph.D., Crystallographer Dr Davide Moiani of DNA SEQ was a key member of the team that integrated the over 60 million XYZ atomic coordinates in the DNASEQ crystal structures library with the algorithm. In 2008 Davide obtained his doctorate in Chemical Engineering at Politecnico di Milano (Italy) and did his post doc at Scripps Research Institute in La Jolla California. Dr Moiani currently is a member of Prof John Tainer’s group at MD Anderson. Davide is co-author of DNA SEQ’s 1 patent and 2 White Papers. Davide Moiani currently works at the Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center. Davide does research in Physical Chemistry, Chemical Biology and Biochemistry.
DEEP LEARNING & REINFORCEMENT LEARNING RESEARCHER
Dmytro Korenkevych, Ph.D., is a deep learning and a reinforcement learning researcher. He received his B.S. and M.S. from Moscow Institute of Physics and Technology and his PhD from the University of Florida. His PhD thesis focuses on machine learning approaches to problems in biomedical domain. After graduation, Dmytro joined D-Wave Systems as a machine learning researcher. There, he designed machine learning systems that exploit D-Wave quantum hardware to train energy-based learning models. Currently Dmytro is a reinforcement learning researcher at Kindred, where he develops reinforcement learning algorithms and designs deep reinforcement learning systems with application to physical robots
KEY TECHNOLOGY PARTNERS
Founded in 1999, D-Wave is the leader in the development and delivery of quantum computing systems, software, and services and is the world’s first commercial supplier of quantum computers. Our mission is to unlock the power of quantum computing for the world. D-Wave’s systems are being used by some of the world’s most advanced organizations, including Lockheed Martin, Google, NASA Ames, Volkswagen, DENSO, USRA, USC, Los Alamos National Laboratory, and Oak Ridge National Laboratory.
Xtal BioStructures specializes in X-ray crystallography and biophysical characterization, offering structural biology insights through contract research services. XTAL’s mission is to provide high-quality biophysical analysis and structural biology research, custom designed to best meet the needs of our clients. We offer a structural approach to discovery with responsive, agile, and collaborative research.SERVICES: Protein Production and Purification • Biophysical Characterization • X-Ray Crystallography • Epigenetic & Bromodomains